GENMAB AS revenue breakdown overview

GENMAB AS revenue for the last year amounted to 2.88 B EUR, the most of which — 2.88 B EUR — came from its highest performing source at the moment, Antibody Therapeutics, the year earlier bringing 2.21 B EUR. The greatest contribution to the revenue figure was made by Denmark — last year it brought GENMAB AS 2.64 B EUR, and the year before that — 2.15 B EUR.